Angiodynamics (ANGO) Liabilities and Shareholders Equity (2011 - 2026)

Angiodynamics (ANGO) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $267.2 million in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 4.63% year-over-year to $267.2 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $1.1 billion (down 7.61% YoY) and the FY2026 annual result came in at $267.2 million, down 4.63% from the prior year.
• Liabilities and Shareholders Equity improved to $267.2 million in Q2 2026, from $260.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $558.2 million in Q4 2022 to a low of $260.7 million in Q1 2026.
• A 5-year average of $396.5 million and a median of $321.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity advanced 0.74% — and 2024, when it tumbled 41.64%.
• Tracing ANGO's Liabilities and Shareholders Equity over 5 years: stood at $558.2 million in 2022, then dropped by 10.5% to $499.6 million in 2023, then plunged by 41.64% to $291.6 million in 2024, then fell by 7.5% to $269.7 million in 2025, then fell by 0.93% to $267.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $267.2 million (Q2 2026), $260.7 million (Q1 2026), and $269.7 million (Q4 2025), per Business Quant data.